Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has granted equity inducement awards to two new employees. The company's new Chief People Officer Robin Andrulevich received options to purchase 500,000 shares of common stock, while another non-executive employee received options for 125,000 shares.
The options were granted under the 2022 Employment Inducement Award Plan with an exercise price of $5.47 per share, the closing price on August 1, 2025. These 10-year term options vest over four years, contingent on continued employment.
Terns Pharmaceuticals (Nasdaq: TERN), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti a piccola molecola per oncologia e obesità, ha assegnato premi azionari a due nuovi dipendenti. Il nuovo Chief People Officer Robin Andrulevich ha ricevuto opzioni per acquistare 500.000 azioni ordinarie, mentre un altro dipendente non esecutivo ha ottenuto opzioni per 125.000 azioni.
Le opzioni sono state concesse nell'ambito del Piano di Incentivazione all'Assunzione 2022, con un prezzo di esercizio di 5,47 $ per azione, pari al prezzo di chiusura del 1º agosto 2025. Queste opzioni, con durata di 10 anni, maturano in quattro anni, subordinatamente alla permanenza in azienda.
Terns Pharmaceuticals (Nasdaq: TERN), una empresa biofarmacéutica en etapa clínica centrada en desarrollar tratamientos de moléculas pequeñas para oncología y obesidad, ha otorgado incentivos accionarios a dos nuevos empleados. El nuevo Chief People Officer Robin Andrulevich recibió opciones para comprar 500,000 acciones ordinarias, mientras que otro empleado no ejecutivo recibió opciones por 125,000 acciones.
Las opciones fueron concedidas bajo el Plan de Incentivos por Empleo 2022 con un precio de ejercicio de $5.47 por acción, el precio de cierre del 1 de agosto de 2025. Estas opciones con un plazo de 10 años se consolidan en cuatro años, condicionadas a la continuidad laboral.
Terns Pharmaceuticals (나스닥: TERN)는 종양학 및 비만 치료를 위한 저분자 치료제 개발에 주력하는 임상 단계의 바이오제약 회사로, 두 명의 신입 직원에게 주식 인센티브를 부여했습니다. 회사의 새로운 최고인사책임자(Chief People Officer) 로빈 안드룰레비치는 50만 주의 보통주 매수 옵션을 받았으며, 다른 비임원 직원은 12만 5천 주의 옵션을 받았습니다.
이 옵션들은 2022년 고용 유인상여 계획에 따라 부여되었으며, 행사 가격은 2025년 8월 1일 종가인 주당 5.47달러입니다. 10년 만기 옵션은 4년에 걸쳐 베스팅되며, 계속 고용 조건에 따라 부여됩니다.
Terns Pharmaceuticals (Nasdaq : TERN), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements à petites molécules pour l'oncologie et l'obésité, a attribué des récompenses en actions à deux nouveaux employés. Le nouveau Chief People Officer Robin Andrulevich a reçu des options d'achat de 500 000 actions ordinaires, tandis qu'un autre employé non cadre a reçu des options pour 125 000 actions.
Les options ont été accordées dans le cadre du Plan d'Incitation à l'Embauche 2022, avec un prix d'exercice de 5,47 $ par action, correspondant au cours de clôture du 1er août 2025. Ces options d'une durée de 10 ans se consolident sur quatre ans, sous réserve de la poursuite de l'emploi.
Terns Pharmaceuticals (Nasdaq: TERN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Kleinmolekültherapien für Onkologie und Adipositas konzentriert, hat zwei neuen Mitarbeitern Aktienanreizprämien gewährt. Der neue Chief People Officer Robin Andrulevich erhielt Optionen zum Kauf von 500.000 Stammaktien, während ein weiterer nicht-exekutiver Mitarbeiter Optionen für 125.000 Aktien erhielt.
Die Optionen wurden im Rahmen des Anreizplans für Neueinstellungen 2022 mit einem Ausübungspreis von 5,47 $ pro Aktie gewährt, basierend auf dem Schlusskurs vom 1. August 2025. Diese Optionen mit einer Laufzeit von 10 Jahren vesten über vier Jahre und sind an eine fortdauernde Beschäftigung gebunden.
- None.
- None.
FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of August 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees’ acceptance of employment with Terns.
The Company granted to Robin Andrulevich, the Company’s new Chief People Officer, an option to purchase 500,000 shares of Terns common stock as of August 1, 2025, and to the other non-executive employee an option to purchase 125,000 shares of Terns common stock as of August 1, 2025.
The options have a 10-year term and an exercise price per share equal to
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Kaytee Bock
investors@ternspharma.com
Media
Jenna Urban
CG Life
media@ternspharma.com
FAQ
What equity awards did Terns Pharmaceuticals (TERN) grant to its new employees in August 2025?
What is the vesting schedule for Terns Pharmaceuticals' (TERN) August 2025 inducement grants?
What is the exercise price and term for TERN's August 2025 inducement grants?
Who is the new Chief People Officer at Terns Pharmaceuticals (TERN)?
